Effects of succinylcholine on the pharmacodynamics of pipecuronium and pancuronium

M. Y. Dubois, Neal Fleming, D. E. Lea

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To study the effects of succinylcholine on subsequent pharmacodynamics of nondepolarizing muscle relaxants, a comparative pharmacodynamic study was carried out in patients having balanced anesthesia (thiopental, fentanyl, nitrous oxide/oxygen) in whom equipotent doses of pipecuronium (80 μg/kg) and pancuronium (100 μg/kg) were given with or without prior administration of succinylcholine (1 mg/kg). Fifty-two patients were randomly assigned to one of the following four groups: 1, pancuronium (100 μg/kg); 2, pipecuronium (80 μg/kg); 3, succinylcholine (1 mg/kg) plus pancuronium (100 μg/kg); and 4, succinylcholine (1 mg/kg) plus pipecuronium (80 μg/kg). In groups 3 and 4, the nondepolarizing relaxant was given after succinylcholine when the twitch height recovered to 75% of its control value. For maintenance of neuromuscular blockade, additional increments of pancuronium (20 μg/kg) or pipecuronium (15 μg/kg) were given. Neuromuscular function was monitored throughout induction, maintenance, spontaneous recovery, and pharmacologic reversal of the neuromuscular block. Mean onset times for pancuronium (group 1) and pipecuronium (group 2) given without succinylcholine were (mean ± SEM) 2.5 ± 0.3 and 2.8 ± 0.2 min, respectively. Mean onset times (times to maximum twitch depression) of the two drugs given after succinylcholine (groups 3 and 4) were significantly shorter (1.4 ± 0.4 and 1.6 ± 0.1 min, respectively). Clinical durations (i.e., until 25% twitch recovery of pancuronium and pipecuronium) were not significantly different among the four groups, varying from 81.1 ± 5.4 (group 4) to 107.0 ± 17.0 (group 2) min. Incremental doses used for maintenance of neuromuscular blockade had durations of action ranging from 44.5 ± 5.1 min (group 1) to 52.8 ± 7.3 min (group 3) and were not altered by the prior administration of succinylcholine. After the administration of nondepolarizing relaxant, times for spontaneous recovery of twitch height from 10% to 25% of baseline levels were comparable in all groups (from 15.1 ± 1.7 to 19.8 ± 2.2 min). The response to reversal of residual neuromuscular blockade with neostigmine (2.5 mg) and glycopyrrolate (0.5 mg) was identical in all groups. We conclude that during balanced anesthesia, the use of succinylcholine for intubation does not necessitate subsequent alteration in doses of pancuronium or pipecuronium.

Original languageEnglish (US)
Pages (from-to)364-368
Number of pages5
JournalAnesthesia and Analgesia
Volume72
Issue number3
StatePublished - 1991
Externally publishedYes

Fingerprint

Pipecuronium
Pancuronium
Succinylcholine
Neuromuscular Blockade
Balanced Anesthesia
Maintenance
Delayed Emergence from Anesthesia
Glycopyrrolate
Neostigmine
Thiopental
Nitrous Oxide
Fentanyl
Intubation

Keywords

  • neuromuscular relaxants, pipecuronium, pancuronium, succinylcholine
  • pharmacodynamics, neuromuscular relaxants

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Effects of succinylcholine on the pharmacodynamics of pipecuronium and pancuronium. / Dubois, M. Y.; Fleming, Neal; Lea, D. E.

In: Anesthesia and Analgesia, Vol. 72, No. 3, 1991, p. 364-368.

Research output: Contribution to journalArticle

@article{39f019d1ce754e02abcaa8fafd30b80d,
title = "Effects of succinylcholine on the pharmacodynamics of pipecuronium and pancuronium",
abstract = "To study the effects of succinylcholine on subsequent pharmacodynamics of nondepolarizing muscle relaxants, a comparative pharmacodynamic study was carried out in patients having balanced anesthesia (thiopental, fentanyl, nitrous oxide/oxygen) in whom equipotent doses of pipecuronium (80 μg/kg) and pancuronium (100 μg/kg) were given with or without prior administration of succinylcholine (1 mg/kg). Fifty-two patients were randomly assigned to one of the following four groups: 1, pancuronium (100 μg/kg); 2, pipecuronium (80 μg/kg); 3, succinylcholine (1 mg/kg) plus pancuronium (100 μg/kg); and 4, succinylcholine (1 mg/kg) plus pipecuronium (80 μg/kg). In groups 3 and 4, the nondepolarizing relaxant was given after succinylcholine when the twitch height recovered to 75{\%} of its control value. For maintenance of neuromuscular blockade, additional increments of pancuronium (20 μg/kg) or pipecuronium (15 μg/kg) were given. Neuromuscular function was monitored throughout induction, maintenance, spontaneous recovery, and pharmacologic reversal of the neuromuscular block. Mean onset times for pancuronium (group 1) and pipecuronium (group 2) given without succinylcholine were (mean ± SEM) 2.5 ± 0.3 and 2.8 ± 0.2 min, respectively. Mean onset times (times to maximum twitch depression) of the two drugs given after succinylcholine (groups 3 and 4) were significantly shorter (1.4 ± 0.4 and 1.6 ± 0.1 min, respectively). Clinical durations (i.e., until 25{\%} twitch recovery of pancuronium and pipecuronium) were not significantly different among the four groups, varying from 81.1 ± 5.4 (group 4) to 107.0 ± 17.0 (group 2) min. Incremental doses used for maintenance of neuromuscular blockade had durations of action ranging from 44.5 ± 5.1 min (group 1) to 52.8 ± 7.3 min (group 3) and were not altered by the prior administration of succinylcholine. After the administration of nondepolarizing relaxant, times for spontaneous recovery of twitch height from 10{\%} to 25{\%} of baseline levels were comparable in all groups (from 15.1 ± 1.7 to 19.8 ± 2.2 min). The response to reversal of residual neuromuscular blockade with neostigmine (2.5 mg) and glycopyrrolate (0.5 mg) was identical in all groups. We conclude that during balanced anesthesia, the use of succinylcholine for intubation does not necessitate subsequent alteration in doses of pancuronium or pipecuronium.",
keywords = "neuromuscular relaxants, pipecuronium, pancuronium, succinylcholine, pharmacodynamics, neuromuscular relaxants",
author = "Dubois, {M. Y.} and Neal Fleming and Lea, {D. E.}",
year = "1991",
language = "English (US)",
volume = "72",
pages = "364--368",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of succinylcholine on the pharmacodynamics of pipecuronium and pancuronium

AU - Dubois, M. Y.

AU - Fleming, Neal

AU - Lea, D. E.

PY - 1991

Y1 - 1991

N2 - To study the effects of succinylcholine on subsequent pharmacodynamics of nondepolarizing muscle relaxants, a comparative pharmacodynamic study was carried out in patients having balanced anesthesia (thiopental, fentanyl, nitrous oxide/oxygen) in whom equipotent doses of pipecuronium (80 μg/kg) and pancuronium (100 μg/kg) were given with or without prior administration of succinylcholine (1 mg/kg). Fifty-two patients were randomly assigned to one of the following four groups: 1, pancuronium (100 μg/kg); 2, pipecuronium (80 μg/kg); 3, succinylcholine (1 mg/kg) plus pancuronium (100 μg/kg); and 4, succinylcholine (1 mg/kg) plus pipecuronium (80 μg/kg). In groups 3 and 4, the nondepolarizing relaxant was given after succinylcholine when the twitch height recovered to 75% of its control value. For maintenance of neuromuscular blockade, additional increments of pancuronium (20 μg/kg) or pipecuronium (15 μg/kg) were given. Neuromuscular function was monitored throughout induction, maintenance, spontaneous recovery, and pharmacologic reversal of the neuromuscular block. Mean onset times for pancuronium (group 1) and pipecuronium (group 2) given without succinylcholine were (mean ± SEM) 2.5 ± 0.3 and 2.8 ± 0.2 min, respectively. Mean onset times (times to maximum twitch depression) of the two drugs given after succinylcholine (groups 3 and 4) were significantly shorter (1.4 ± 0.4 and 1.6 ± 0.1 min, respectively). Clinical durations (i.e., until 25% twitch recovery of pancuronium and pipecuronium) were not significantly different among the four groups, varying from 81.1 ± 5.4 (group 4) to 107.0 ± 17.0 (group 2) min. Incremental doses used for maintenance of neuromuscular blockade had durations of action ranging from 44.5 ± 5.1 min (group 1) to 52.8 ± 7.3 min (group 3) and were not altered by the prior administration of succinylcholine. After the administration of nondepolarizing relaxant, times for spontaneous recovery of twitch height from 10% to 25% of baseline levels were comparable in all groups (from 15.1 ± 1.7 to 19.8 ± 2.2 min). The response to reversal of residual neuromuscular blockade with neostigmine (2.5 mg) and glycopyrrolate (0.5 mg) was identical in all groups. We conclude that during balanced anesthesia, the use of succinylcholine for intubation does not necessitate subsequent alteration in doses of pancuronium or pipecuronium.

AB - To study the effects of succinylcholine on subsequent pharmacodynamics of nondepolarizing muscle relaxants, a comparative pharmacodynamic study was carried out in patients having balanced anesthesia (thiopental, fentanyl, nitrous oxide/oxygen) in whom equipotent doses of pipecuronium (80 μg/kg) and pancuronium (100 μg/kg) were given with or without prior administration of succinylcholine (1 mg/kg). Fifty-two patients were randomly assigned to one of the following four groups: 1, pancuronium (100 μg/kg); 2, pipecuronium (80 μg/kg); 3, succinylcholine (1 mg/kg) plus pancuronium (100 μg/kg); and 4, succinylcholine (1 mg/kg) plus pipecuronium (80 μg/kg). In groups 3 and 4, the nondepolarizing relaxant was given after succinylcholine when the twitch height recovered to 75% of its control value. For maintenance of neuromuscular blockade, additional increments of pancuronium (20 μg/kg) or pipecuronium (15 μg/kg) were given. Neuromuscular function was monitored throughout induction, maintenance, spontaneous recovery, and pharmacologic reversal of the neuromuscular block. Mean onset times for pancuronium (group 1) and pipecuronium (group 2) given without succinylcholine were (mean ± SEM) 2.5 ± 0.3 and 2.8 ± 0.2 min, respectively. Mean onset times (times to maximum twitch depression) of the two drugs given after succinylcholine (groups 3 and 4) were significantly shorter (1.4 ± 0.4 and 1.6 ± 0.1 min, respectively). Clinical durations (i.e., until 25% twitch recovery of pancuronium and pipecuronium) were not significantly different among the four groups, varying from 81.1 ± 5.4 (group 4) to 107.0 ± 17.0 (group 2) min. Incremental doses used for maintenance of neuromuscular blockade had durations of action ranging from 44.5 ± 5.1 min (group 1) to 52.8 ± 7.3 min (group 3) and were not altered by the prior administration of succinylcholine. After the administration of nondepolarizing relaxant, times for spontaneous recovery of twitch height from 10% to 25% of baseline levels were comparable in all groups (from 15.1 ± 1.7 to 19.8 ± 2.2 min). The response to reversal of residual neuromuscular blockade with neostigmine (2.5 mg) and glycopyrrolate (0.5 mg) was identical in all groups. We conclude that during balanced anesthesia, the use of succinylcholine for intubation does not necessitate subsequent alteration in doses of pancuronium or pipecuronium.

KW - neuromuscular relaxants, pipecuronium, pancuronium, succinylcholine

KW - pharmacodynamics, neuromuscular relaxants

UR - http://www.scopus.com/inward/record.url?scp=0025810178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025810178&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 364

EP - 368

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 3

ER -